Cencora Inc.
08/12/2026 | Press release | Distributed by Public on 08/12/2026 10:38
Regulation FD Disclosure (Form 8-K)
Item 7.01. Regulation FD Disclosure.
Beginning July 1, 2026, certain Walgreens volume that was being serviced by Cencora, Inc. (the "Company" or "Cencora") separate from the prime vendor agreement began moving outside the Company. The prime vendor agreement, which remains unchanged, constitutes the vast majority of the Company's business with Walgreens. This was fully contemplated in Cencora's August 5, 2026 commentary on fourth quarter expectations for its U.S. Healthcare Solutions segment.
Cencora is reaffirming its previously issued adjusted diluted EPS guidance range of $17.75 to $17.95 for fiscal year 2026.
Cencora Inc. published this content on August 12, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on August 12, 2026 at 16:41 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]